Format

Send to

Choose Destination
See comment in PubMed Commons below
J Visc Surg. 2011 Jun;148(3):e161-70. doi: 10.1016/j.jviscsurg.2011.05.008. Epub 2011 Jun 28.

Management of esophageal adenocarcinoma.

Author information

  • 1Service d'hépato-gastroentérologie, CHU de Poitiers, 2, rue de la Milétrie, 86000 Poitiers cedex, France. davidtougeron@hotmail.fr

Abstract

The incidence of esophageal adenocarcinoma is increasing in Western countries with a tendency to exceed that of squamous-cell carcinoma. Prognosis is unfavorable with 5-year survival less than 15%, irrespective of treatment and the stage. At the time of diagnosis, more than two thirds of patients have a non-operable cancer because of extension or associated co-morbidities. Most studies have included different tumoral locations (esophagus and stomach) and different histological types (adenocarcinoma and squamous-cell carcinoma), making it difficult to interpret results. Surgery is currently the standard treatment for small tumors. Surgery should be preceded by neo-adjuvant treatment for patients with locally advanced resectable tumors, either preoperative chemotherapy or preoperative chemoradiation therapy. The therapeutic choice should be decided during multidisciplinary meetings according to patient and tumor characteristics and the expertise of the center. For patients with contraindications to surgery, exclusive chemoradiation therapy is recommended. Herein we reviewed and synthesized the different therapeutic strategies for esophageal adenocarcinoma.

Copyright © 2011 Elsevier Masson SAS. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk